[{"orgOrder":0,"company":"Sichuan Kelun Pharmaceutical","sponsor":"Levena Biopharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Levena Biopharma, A Sorrento Company, Announces Positive Clinical Data for Its Out-Licensed A166 Product Candidate, A Third-Generation Anti-HER2-ADC, In Treating Heavily Pretreated HER2-Positive Breast Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Sichuan Kelun Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$1,407.0 million","upfrontCash":"$47.0 million","newsHeadline":"China\u2019s Kelun Pharma Jumps on Licensing New Cancer Drug to Holland\u2019s Merck Sharp & Dohme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Sichuan Kelun Pharmaceutical","sponsor":"Levena Biopharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and Levena Biopharma, a Sorrento Company, are to Present Positive Clinical Progress of A166, an Anti-HER2 ADC, in Treating Locally Advanced or Metastatic HER2-Positive Breast Cancer Patients at the ASCO 20","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Sichuan Kelun Pharmaceutical
A166 is an antibody-drug conjugate (ADC) composed of an anti-HER2 antibody conjugated to Duostatin-5, a novel anti-microtubule Auristatin derivative, via a proprietary stable covalent linker.
The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing of upfront cash in exchange for ex-China rights to a “macromolecular tumor project".
A166, a third-generation antibody-drug conjugate with tubulin inhibitor Duo-5 toxin, cleavable linker and site-specific K-Lock conjugation chemistry, demonstrated antitumor activity with meaningful responses in heavily pretreated subjects with HER2-positive breast cancer.